Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells.

@article{Burgos2012CannabinoidAW,
  title={Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells.},
  author={Elisa Burgos and Diego G{\'o}mez-Nicola and David Villa Pascual and Mar{\'i}a Isabel Mart{\'i}n and Manuel Nieto-Sampedro and Carlos Goicoechea},
  journal={European journal of pharmacology},
  year={2012},
  volume={682 1-3},
  pages={62-72}
}
Spinal glial activation contributes to the development and maintenance of chronic pain states, including neuropathic pain of diverse etiologies. Cannabinoid compounds have shown antinociceptive properties in a variety of neuropathic pain models and are emerging as a promising class of drugs to treat neuropathic pain. Thus, the effects of repeated treatment with WIN 55,212-2, a synthetic cannabinoid agonist, were examined throughout the development of paclitaxel-induced peripheral neuropathy… CONTINUE READING